Clinical Trial Update: Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Bay 59-8862 for aggressive, refractory Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• BAY 59-8862

Snippet

Sponsor: Bayer | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED